AACR Annual Meeting 2019: Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including...
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including...
Assessing new anticancer therapeutics in clinical trials is a vital step in evaluating the toxicity and efficacy of treatment...
While immunotherapy may be the latest tool in the treatment armamentarium for cancer, many ongoing clinical trials are assessing...
The AACR Annual Meeting 2018 drew more than 22,600 people to Chicago, providing a front-row seat to some exciting...
Monday ushered in a ray of hope and promise for the lung cancer community at the AACR Annual Meeting...
Patient enrollment in clinical trials has long been on the minds of oncologists and researchers. In 1990, fewer than...
recent data suggest that there is another potential contender for a biomarker-based FDA approval: a targeted therapeutic called larotrectinib...
On March 23, the U.S. Food and Drug Administration announced the first-ever approval of a treatment for patients with...
Now that a plethora of clinical trials have established positive responses from immunotherapies—immune checkpoint inhibitors, in particular—in patients with...
SABCS is a comprehensive scientific meeting that provides the latest information on prevention, diagnosis, and treatment of breast cancer...